The Phase 1 data shows best-in-class potential for soquelitinib in atopic dermatitis with durable drug-free remissions, a key differentiator from approved systemic therapies. The Phase 2 SIERRA1 trial enrollment and Angel Pharma's China trial results (late 2026) are the next catalysts. Monitor for partnership or licensing interest given the differentiated profile.
Price Chart
Executive Summary
Corvus Pharmaceuticals presented final Phase 1 data for soquelitinib in atopic dermatitis at the SID Annual Meeting, showing 75% EASI 75 achievement in the 8-week cohort and durable drug-free remissions with no rebound. The biomarker data supports the novel ITK inhibition mechanism, including persistent Treg induction and JAK-STAT pathway modulation. The company is enrolling a Phase 2 SIERRA1 trial (~200 patients) and its partner Angel Pharmaceuticals is enrolling a Phase 1b/2 trial in China.
Key Facts
- Phase 1 trial enrolled 72 patients with moderate-to-severe atopic dermatitis; 35% had prior systemic therapy
- Cohort 4 (200 mg BID, 8 weeks): 75% achieved EASI 75, 25% achieved EASI 90, 33% achieved IGA 0/1
- Cohort 3 (200 mg BID, 4 weeks): 50% achieved EASI 75, 8% achieved EASI 90, 25% achieved IGA 0/1
- No disease rebound observed during drug-free follow-up (30-90 days); no rescue medications required
- Adverse events occurred in 41.7% of soquelitinib and 41.7% of placebo patients; all Grade 1-2, no dose modifications
- Biomarker data shows dose-dependent reduction in Th2 cells, persistent Treg increase, and JAK-STAT pathway inhibition
- Phase 2 SIERRA1 trial enrolling ~200 patients with 12-week treatment and 90-day follow-up
- Angel Pharmaceuticals enrolling Phase 1b/2 trial in China; initial results anticipated late 2026
Financial Impact
No financial data in filing; clinical-stage biotech with no approved products or revenue
Risk Factors
- Phase 1 data is small (72 patients) and may not replicate in larger Phase 2/3 trials
- Competition from approved JAK inhibitors and biologics with established safety profiles
- No revenue or approved products; dependent on capital markets for funding
- Regulatory path uncertain; FDA may require additional trials before approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-003397 |
| Exhibit: exh_991.htm | 0001171843-26-003397 |
| Document: 0001171843-26-003397-index-headers.html | 0001171843-26-003397 |
| Document: 0001171843-26-003397-index.html | 0001171843-26-003397 |
| Document: 0001171843-26-003397.txt | 0001171843-26-003397 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 6w ago | Institutional Cluster | $14.46 $12.42 | ▼ −14.11% | ▼ −13.58% | $10.90 (−24.62%) |
Jul 22, 2026 10w ago | 8-K | $13.68 $14.33 | ▲ +4.75% | ▲ +1.44% | $10.90 (−20.32%) |
Jun 11, 2026 16w ago | Institutional Cluster | $11.60 $16.20 | ▲ +39.66% | ▲ +37.76% | $10.90 (−6.03%) |
May 14, 2026 20w ago | 8-K | $13.66 $11.93 | ▼ −12.63% | ▼ −11.77% | $10.90 (−20.18%) |
May 7, 2026 21w ago | 8-K | $15.55 $11.12 | ▼ −28.49% | ▼ −28.51% | $10.90 (−29.90%) |
Apr 24, 2026 23w ago | DEFA14A | $15.92 $12.83 | ▼ −19.41% | ▼ −24.37% | $10.90 (−31.53%) |
Apr 21, 2026 23w ago | Press Release | $17.14 $12.21 | ▼ −28.76% | ▼ −33.68% | $10.90 (−36.41%) |
Mar 12, 2026 29w ago | Press Release | $15.32 $15.17 | ▼ −0.98% | ▼ −4.57% | $10.90 (−28.85%) |
Mar 5, 2026 30w ago | Press Release | $15.80 $14.71 | ▼ −6.87% | ▼ −4.82% | $10.90 (−30.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access